We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

BRUKER

BRUKER offers high-performance scientific instruments and high-value analytical and diagnostic solutions that enable ... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

MALDI-TOF Can Predict Antimicrobial Resistance in Clinical Samples

By LabMedica International staff writers
Posted on 27 Jan 2022
Print article
Image: The Microflex Biotyper MALDI-TOF Mass Spectrometry System for fast, accurate and cost-effective microbial identification (Photo courtesy of Bruker Daltonics)
Image: The Microflex Biotyper MALDI-TOF Mass Spectrometry System for fast, accurate and cost-effective microbial identification (Photo courtesy of Bruker Daltonics)
Antimicrobial-resistant bacteria and fungi pose a serious and increasing threat to the achievements of modern medicine. Infections with antimicrobial-resistant pathogens are associated with substantial morbidity, mortality and healthcare costs.

Matrix-assisted laser desorption/ionization–time of flight (MALDI-TOF) mass spectrometry enables rapid microbial species identification. In only a few minutes, MALDI-TOF mass spectrometry can be used to characterize the protein composition of single bacterial or fungal colonies, and the results are available usually within 24 hours after sample collection.

Medical Microbiologists at the University of Basel (Basel, Switzerland) and their colleagues developed a database, which they dubbed the Database of Resistance Information on Antimicrobials and MALDI-TOF Mass Spectra, or DRIAMS, by collecting MALDI-TOF mass spectra and resistance information on more than 30,000 clinical isolates from four different Swiss clinical labs.

The largest collection within DRIAMS, called DRIAMS-A, came from University Hospital Basel (Basel, Switzerland) and included 145,341 mass spectra. Most of the spectra could be generated from clinical samples within 24 hours. All laboratories used the Microflex Biotyper System (Bruker Daltonics, Bremen, Germany), which is a widely used MALDI-TOF mass spectrometry system. Resistance categories for bacteria were determined using either microdilution assays (VITEK 2, BioMérieux, Marcy l'Etoile France), minimum inhibitory concentration (MIC) stripe tests (Liofilchem, Roseto degli Abruzzi, Italy) or disc diffusion tests (Thermo Fisher Scientific, Waltham MA, USA). Resistance categories for yeast were determined using Thermo Fisher Scientific’s Sensititre Yeast One.

The investigators particular focused their analyses on three key clinical pathogens, Staphylococcus aureus, Escherichia coli, and Klebsiella pneumoniae, and antibiotics used to treat infections they cause. For all three, they reported a high overall performance. The classifier could predict S. aureus resistance to oxacillin with 80% accuracy as well as E. coli and K. pneumoniae resistance to ceftriaxone currently with 74% accuracy for both. For 31 of the 42 antibiotics studied, the classifier generated could correctly classify resistance with 80% accuracy. In a retrospective clinical case study, the researchers reviewed 416 cases with positive S. aureus, E. coli, and K. pneumoniae cultures. For 63 of these, an infectious disease specialist was consulted to help guide antibiotic treatment.

The authors concluded that their retrospective clinical case study shows that their classifier might have a beneficial impact on patient treatment and promote antibiotic stewardship. MALDI-TOF mass spectra-based machine learning may thus be an important new tool for treatment optimization. The study was published on January 10, 2022 in the journal Nature Medicine.

Related Links:
University of Basel
University Hospital Basel
Bruker Daltonics
BioMérieux
Liofilchem
Thermo Fisher Scientific


Platinum Supplier
SARS-CoV-2 Pooling Test
Extensive SARS-CoV-2 Pooling
New
Washer Dispenser
EL406
New
Silver Supplier
Helicobacter Pylori Test
AB HP UREASE TEST
New
Electrolyte Analyzer
K-Lite 5 Series

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: Guidance UTI provides personalized results in less than one day from receipt at lab (Photo courtesy of Pathnostics)

Rapid Result Test for Complicated Urinary Tract Infections Proves Superior to Standard Urine Culture

Complicated urinary tract infections (cUTIs) are a significant burden on individual health and healthcare resources that must be diagnosed and treated early and accurately to reduce the risk of poor outcomes.... Read more

Hematology

view channel
Image: The CS-2500 analyzer features pre-analytic sample checks and four detection methods simultaneously on a single platform – coagulation end-point, chromogenic kinetic analysis, turbidimetric immunoassay and automated platelet aggregation (Photo courtesy of Sysmex)

Microvascular/Endothelial Dysfunction Contributes to Post-COVID Syndrome Pathogenesis

Post-COVID syndrome (PCS) or Long-COVID is an increasingly recognized complication of acute SARS-CoV-2 infection, characterized by persistent fatigue, reduced exercise tolerance chest pain, shortness of... Read more

Industry

view channel
Image: Sales of lateral flow assays in clinical testing are expected to register a CAGR of 5% through 2032 (Photo courtesy of Pexels)

Global Lateral Flow Assays Market to Surpass USD 11.5 Billion by 2032 Due to Evolving Applications

The global lateral flow assays market was valued at USD 7.2 billion in 2021 and is projected to register a CAGR of 4.7% during 2022-2032 to surpass USD 11.7 billion by the end of 2032, driven by the growing... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.